Scopus
EXPORT Sarli v

Leonidis G., Sigala I., Spathakis M., Kolios G., Giannakouros T., Nikolakaki E., Sarli V.
Synthesis of novel SRPK1-targeting hybrid compounds incorporating antimetabolites for cancer therapy
(2025) RSC Medicinal Chemistry, 16 (12), pp. 6285 - 6298, Cited 0 times.
DOI: 10.1039/d5md00731c

Leonidis G., Dalezis P., Trafalis D., Beis D., Giardoglou P., Koukiali A., Sigala I., Nikolakaki E., Sarli V.
Synthesis and Biological Evaluation of a c(RGDyK) Peptide Conjugate of SRPIN803
(2021) ACS Omega, 6 (42), pp. 28379 - 28393, Cited 4 times.
DOI: 10.1021/acsomega.1c04576

Chatzisideri T., Leonidis G., Karampelas T., Skavatsou E., Velentza-Almpani A., Bianchini F., Tamvakopoulos C., Sarli V.
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine
(2022) Journal of Medicinal Chemistry, 65 (1), pp. 271 - 284, Cited 19 times.
DOI: 10.1021/acs.jmedchem.1c01468

Tsitouroudi F., Sarli V., Poulcharidis D., Pitou M., Katranidis A., Choli-Papadopoulou T.
Aza-reversine promotes reprogramming of lung (Mrc-5) and differentiation of mesenchymal cells into osteoblasts
(2021) Materials, 14 (18), art. no. 5385, Cited 4 times.
DOI: 10.3390/ma14185385

Voura M., Anwar S., Thysiadis S., Κhan P., Dalezis P., Trafalis D.T., Hassan M.I., Sarli V.
Synthesis and biological activity of bisindole derivatives as novel MARK4 inhibitors
(2022) European Journal of Medicinal Chemistry Reports, 6, art. no. 100076, Cited 13 times.
DOI: 10.1016/j.ejmcr.2022.100076

Siokatas C., Lampropoulou A., Smina A., Soupsana K., Kontostathi M., Karra A.-V., Karampelas T., Politou A.S., Christoforidis S., Tamvakopoulos C., Sarli V.
Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the “Undruggable” MYC
(2024) ACS Pharmacology and Translational Science, 7 (12), pp. 3955 - 3968, Cited 5 times.
DOI: 10.1021/acsptsci.4c00452

Leonidis G., Koukiali A., Sigala I., Tsimaratou K., Beis D., Giannakouros T., Nikolakaki E., Sarli V.
Synthesis and Anti-Angiogenic Activity of Novel c(RGDyK) Peptide-Based JH-VII-139-1 Conjugates
(2023) Pharmaceutics, 15 (2), art. no. 381, Cited 3 times.
DOI: 10.3390/pharmaceutics15020381

Voura M., Sflakidou E., Sarli V.
Modulators of ROS/NF-kB Signaling in Cancer Therapy
(2022) Handbook of Oxidative Stress in Cancer: Mechanistic Aspects, 3, pp. 2165 - 2184, Cited 1 times.
DOI: 10.1007/978-981-15-9411-3_135

Trafalis D.T., Sagredou S., Dalezis P., Voura M., Fountoulaki S., Nikoleousakos N., Almpanakis K., Deligiorgi M.V., Sarli V.
Anticancer activity of triazolo-thiadiazole derivatives and inhibition of akt1 and akt2 activation
(2021) Pharmaceutics, 13 (4), art. no. 493, Cited 11 times.
DOI: 10.3390/pharmaceutics13040493

Sflakidou E., Dalezis P., Trafalis D.T., Sarli V.
Synthesis and antiproliferative activities of steroidal lactam conjugates bearing a new nitrogen mustard
(2023) European Journal of Medicinal Chemistry, 249, art. no. 115133, Cited 6 times.
DOI: 10.1016/j.ejmech.2023.115133

Voura M., Sflakidou E., Sarli V.
Modulators of ROS/NF-κB Signaling in Cancer Therapy
(2022) Handbook of Oxidative Stress in Cancer: Therapeutic Aspects: Volume 1, 1, pp. 3611 - 3628, Cited 1 times.
DOI: 10.1007/978-981-16-5422-0_169

Chatzisideri T., Dalezis P., Leonidis G., Bousis S., Trafalis D., Bianchini F., Sarli V.
Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins
(2021) Future Medicinal Chemistry, 13 (10), pp. 877 - 895, Cited 6 times.
DOI: 10.4155/fmc-2020-0309


Kyrila G., Katsoulas A., Schoretsaniti V., Rigopoulos A., Rizou E., Doulgeridou S., Sarli V., Samanidou V., Touraki M.
Bisphenol A removal and degradation pathways in microorganisms with probiotic properties
(2021) Journal of Hazardous Materials, 413, art. no. 125363, Cited 106 times.
DOI: 10.1016/j.jhazmat.2021.125363


Sflakidou E., Leonidis G., Foroglou E., Siokatas C., Sarli V.
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
(2022) Molecules, 27 (19), art. no. 6632, Cited 43 times.
DOI: 10.3390/molecules27196632

Christos S., Georgios L., Vasiliki S.
Terpenoids as Chemopreventive Agents and Their Interpretation in Animal Models and Human Clinical Trials
(2023) Handbook of Animal Models and its Uses in Cancer Research, pp. 727 - 745, Cited 0 times.
DOI: 10.1007/978-981-19-3824-5_36

Tsanakopoulou M., Dalezis P., Karakousi C.-V., Schina D., Trafalis D., Malamidou-Xenikaki E., Sarli V.
Synthesis and Cytotoxic Effects of 3,6-Bis-indolyl 2,5-Dihydroxybenzoquinone Acetates
(2022) ChemistrySelect, 7 (32), art. no. e202202060, Cited 0 times.
DOI: 10.1002/slct.202202060

Voura M., Anwar S., Sigala I., Parasidou E., Fragoulidou S., Hassan M.I., Sarli V.
Synthesis, Structural Modification, and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors
(2023) ACS Pharmacology and Translational Science, 6 (7), pp. 1052 - 1074, Cited 10 times.
DOI: 10.1021/acsptsci.3c00084

Nikoleousakos N., Dalezis P., Polonifi A., Geromichalou E.G., Sagredou S., Alifieris C.E., Deligiorgi M.V., Sarli V., Trafalis D.T.
Cytocidal antitumor effects against human ovarian cancer cells induced by b-lactam steroid alkylators with targeted activity against poly (Adp-ribose) polymerase (parp) enzymes in a cell-free assay
(2021) Biomedicines, 9 (8), art. no. 1028, Cited 5 times.
DOI: 10.3390/biomedicines9081028

Anwar S., Ahmed A., Sarli V., Hassan I.
Editorial: Protein kinase inhibitors in neurodegeneration and cancer targeted therapies
(2024) Frontiers in Cell and Developmental Biology, 12, art. no. 1413293, Cited 2 times.
DOI: 10.3389/fcell.2024.1413293

Rantzios K., Chatzimentor O.-E., Leonidis G., Giuliani J., Sigala I., Sarli V.
Synthesis and Biological Screening of Structurally Modified Phaeosphaeride Analogues
(2025) Molecules, 30 (9), art. no. 2016, Cited 0 times.
DOI: 10.3390/molecules30092016

Sflakidou E., Adhikari B., Siokatas C., Wolf E., Sarli V.
Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases
(2024) ACS Pharmacology and Translational Science, 7 (11), pp. 3488 - 3501, Cited 11 times.
DOI: 10.1021/acsptsci.4c00405

Sagredou S., Dalezis P., Papadopoulou E., Voura M., Deligiorgi M.V., Nikolaou M., Panayiotidis M.I., Nasioulas G., Sarli V., Trafalis D.T.
Effects of a novel thiadiazole derivative with high anticancer activity on cancer cell immunogenic markers: Mismatch repair system, pd-l1 expression, and tumor mutation burden
(2021) Pharmaceutics, 13 (6), art. no. 885, Cited 3 times.
DOI: 10.3390/pharmaceutics13060885